PerkinElmer, Inc. (NYSE:PKI) Stake Lifted by Rhumbline Advisers

Rhumbline Advisers raised its holdings in shares of PerkinElmer, Inc. (NYSE:PKIGet Rating) by 13.5% in the second quarter, HoldingsChannel reports. The institutional investor owned 194,112 shares of the medical research company’s stock after purchasing an additional 23,135 shares during the quarter. Rhumbline Advisers’ holdings in PerkinElmer were worth $27,607,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Clear Street Markets LLC boosted its holdings in PerkinElmer by 417.6% during the second quarter. Clear Street Markets LLC now owns 264 shares of the medical research company’s stock worth $38,000 after buying an additional 213 shares in the last quarter. Crewe Advisors LLC boosted its holdings in PerkinElmer by 546.8% during the second quarter. Crewe Advisors LLC now owns 401 shares of the medical research company’s stock worth $57,000 after buying an additional 339 shares in the last quarter. Covestor Ltd boosted its holdings in PerkinElmer by 25.1% during the first quarter. Covestor Ltd now owns 359 shares of the medical research company’s stock worth $63,000 after buying an additional 72 shares in the last quarter. Heritage Financial Services LLC acquired a new position in PerkinElmer in the 2nd quarter worth approximately $80,000. Finally, MV Capital Management Inc. boosted its stake in PerkinElmer by 1,085.1% in the 1st quarter. MV Capital Management Inc. now owns 557 shares of the medical research company’s stock worth $97,000 after purchasing an additional 510 shares during the period. 77.06% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

PKI has been the subject of a number of recent analyst reports. Bank of America lowered shares of PerkinElmer from a “buy” rating to a “neutral” rating and set a $178.00 price objective for the company. in a research note on Tuesday, August 2nd. Stifel Nicolaus lowered shares of PerkinElmer from a “buy” rating to a “hold” rating and decreased their price objective for the stock from $190.00 to $170.00 in a research note on Thursday, August 18th. TheStreet lowered shares of PerkinElmer from a “b” rating to a “c+” rating in a research note on Friday, September 23rd. StockNews.com lowered shares of PerkinElmer from a “buy” rating to a “hold” rating in a research note on Thursday, November 10th. Finally, Barclays cut their target price on shares of PerkinElmer from $140.00 to $120.00 and set an “underweight” rating for the company in a research report on Thursday, October 6th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $168.44.

PerkinElmer Stock Up 0.6 %

PKI stock opened at $137.37 on Thursday. PerkinElmer, Inc. has a 12-month low of $113.46 and a 12-month high of $203.16. The company has a quick ratio of 1.84, a current ratio of 2.10 and a debt-to-equity ratio of 0.55. The company has a market cap of $17.34 billion, a price-to-earnings ratio of 28.03, a PEG ratio of 0.37 and a beta of 1.15. The company has a 50 day moving average of $129.50 and a two-hundred day moving average of $139.27.

PerkinElmer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, February 10th. Stockholders of record on Friday, January 20th will be issued a dividend of $0.07 per share. The ex-dividend date of this dividend is Thursday, January 19th. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.20%. PerkinElmer’s dividend payout ratio is currently 5.71%.

PerkinElmer Profile

(Get Rating)

PerkinElmer, Inc provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services.

Featured Stories

Want to see what other hedge funds are holding PKI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PerkinElmer, Inc. (NYSE:PKIGet Rating).

Institutional Ownership by Quarter for PerkinElmer (NYSE:PKI)

Receive News & Ratings for PerkinElmer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer and related companies with MarketBeat.com's FREE daily email newsletter.